
Synamet100mg + 10
Healthcare Pharmaceuticals Ltd.
Levodopa + Carbidopa is a combination antiparkinsonian medicine used to treat conditions involving dopamine deficiency in the brain.
Levodopa + Carbidopa is a combination antiparkinsonian medicine used to treat conditions involving dopamine deficiency in the brain.
Levodopa + Carbidopa is not effective for drug-induced (secondary) parkinsonism caused by antipsychotic medicines, and is not a cure — it controls symptoms only for as long as it is taken.
Dosage of Levodopa + Carbidopa must be individualized by a physician according to the patient's response; the tablets are usually adjustable/scored to allow dose titration. The information below reflects typical adult dosing for the 25 mg carbidopa/100 mg levodopa (25/100) and 25 mg carbidopa/250 mg levodopa (25/250) immediate-release strengths; extended-release and other local strengths are dosed differently — follow the prescribing physician's instructions and the specific product's labeling.
| Situation | Typical adult dosing |
|---|---|
| Patients not currently taking levodopa | Start with one 25 mg/100 mg tablet three times daily. May increase by one tablet every day or every other day, as needed, until a dose of 8 tablets/day is reached, or until optimal response. |
| Switching from levodopa alone | Stop levodopa at least 12 hours beforehand. Begin Levodopa + Carbidopa at roughly 25% of the previous levodopa dose. Patients previously on <1500 mg/day levodopa: start one 25 mg/100 mg tablet 3–4 times daily; on >1500 mg/day: start one 25 mg/250 mg tablet 3–4 times daily. |
| Maintenance | Adjust to the lowest effective dose that controls symptoms, typically providing at least 70–100 mg of carbidopa per day; most patients are maintained on 3–8 tablets/day in divided doses. Doses above 8 tablets/day (of the 25/100 strength) are not generally recommended. |
| Renal impairment | No formal dose adjustment is established; use with caution and titrate slowly, as levodopa/carbidopa metabolites are renally excreted. |
| Hepatic impairment | No formal dose adjustment is established; use with caution in significant hepatic disease. |
| Pediatric patients | Not recommended — safety and effectiveness in patients under 18 years have not been established (see Pediatric Uses). |
Side effects of Levodopa + Carbidopa can be dose-related and often overlap with disease-related symptoms. Report new or worsening symptoms to a physician.
Levodopa + Carbidopa is contraindicated in the following situations:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.